ly367385 Search Results


ly367385  (Tocris)
94
Tocris ly367385
Ly367385, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/Tocris
Average 94 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
ly367385 hydrochloride  (MedChemExpress)
94
MedChemExpress ly367385 hydrochloride
Ly367385 Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385 hydrochloride/product/MedChemExpress
Average 94 stars, based on 1 article reviews
ly367385 hydrochloride - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
mglur1 antagonist ly367385  (MedChemExpress)
93
MedChemExpress mglur1 antagonist ly367385
Mglur1 Antagonist Ly367385, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mglur1 antagonist ly367385/product/MedChemExpress
Average 93 stars, based on 1 article reviews
mglur1 antagonist ly367385 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
ly367385  (Hello Bio Inc)
90
Hello Bio Inc ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly367385, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/Hello Bio Inc
Average 90 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
2-methyl-4-carboxyphenyglycine ly367385  (Eli Lilly)
90
Eli Lilly 2-methyl-4-carboxyphenyglycine ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
2 Methyl 4 Carboxyphenyglycine Ly367385, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2-methyl-4-carboxyphenyglycine ly367385/product/Eli Lilly
Average 90 stars, based on 1 article reviews
2-methyl-4-carboxyphenyglycine ly367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ly367385  (CH Instruments)
90
CH Instruments ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly367385, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/CH Instruments
Average 90 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
selective mglur 1 antagonist ly 367385  (Robust LTD)
90
Robust LTD selective mglur 1 antagonist ly 367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Selective Mglur 1 Antagonist Ly 367385, supplied by Robust LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selective mglur 1 antagonist ly 367385/product/Robust LTD
Average 90 stars, based on 1 article reviews
selective mglur 1 antagonist ly 367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ly367385  (MedChemExpress)
93
MedChemExpress ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly367385, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/MedChemExpress
Average 93 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
ly367385  (Macquarie Bank)
90
Macquarie Bank ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly367385, supplied by Macquarie Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/Macquarie Bank
Average 90 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ly367385  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies ly367385
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly367385, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly367385/product/Federation of European Neuroscience Societies
Average 90 stars, based on 1 article reviews
ly367385 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ly 367385 ((s)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid  (Biotrend Chemicals)
90
Biotrend Chemicals ly 367385 ((s)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid
(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and <t>MPEP</t> (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, <t>then</t> <t>DNQX</t> (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.
Ly 367385 ((S) (+) A Amino 4 Carboxy 2 Methylbenzeneacetic Acid, supplied by Biotrend Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly 367385 ((s)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid/product/Biotrend Chemicals
Average 90 stars, based on 1 article reviews
ly 367385 ((s)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and MPEP (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, then DNQX (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.

Journal: bioRxiv

Article Title: Bidirectional Long-Term Synaptic Zinc Plasticity at Mouse Glutamatergic Synapses

doi: 10.1101/320671

Figure Lengend Snippet: (A) Left: Time course of AMPAR EPSC amplitude before and after HFS, and NMDAR EPSC amplitude before and after subsequent ZX1 application (blue); and similar time course in interleaved control experiments (without HFS, red). Right: Example NMDAR EPSCs before and after ZX1 application. (B) Left: Same time course as in A but in the presence of LY367385 (100 μM) and MPEP (4 μM) (green). Red line shows controls replotted from A . Right: Example NMDAR EPSCs before and after ZX1 application. For (A-B) , after obtaining a stable baseline of AMPAR EPSCs, HFS was delivered, then DNQX (20 μM) was applied. NMDAR EPSCs were then recorded at +40 mV normalized to the baseline NMDAR EPSC amplitude before ZX1 application. The switch from AMPAR to NMDAR EPSC time course, and the renormalization of EPSC amplitude are indicated by a gap and restart of timing in the x-axis. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘HFS’: n=6; ‘HFS + LY367385, MPEP’: n=5. HFS reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP. Kruskal-Wallis test/Dunn: *p=0.01. (D) Dose-response of NMDAR EPSCs (% baseline) for increasing concentrations of ifenprodil, in controls (red) and after HFS (blue). ‘Control’: n=3-5 per concentration; ‘HFS’: n=3-4 per concentration. IC 50 of ifenprodil, from dose-responses in D . n.s. p=0.97, comparison of fits, extra sum-of-squares F test. Values represent mean ± SEM. Star (*) indicates p<0.05.

Article Snippet: The following drugs were purchased from HelloBio: SR95531 hydrobromide, DL-AP5, DNQX disodium salt, ifenprodil, MPEP hydrochloride, LY367385, and (S)-3,5-Dihydroxyphenylglycine (DHPG).

Techniques: Concentration Assay

(A) Time course of AMPAR EPSC amplitude before and after HFS in the presence of APV (50 μM), and before and after subsequent ZX1 application. EPSC % baseline after HFS (mins. 19-23): n=9, *p=0.0008, one-sample t test vs. 100%. (B) Same time course as in A but in the presence of LY367385 (100 μM), MPEP (4 μM), and APV (50 μM). EPSC % baseline after HFS (mins. 19-23): n=6, *p=0.041, one-sample t test vs. 100%. For (A-B) , star (*) indicates significant LTP. To examine ZX1 potentiation after HFS, similar approach and renormalization as in 1C was performed. Red line shows the time course of AMPAR EPSC amplitude before and after ZX1 application in control replotted from 1B . Example traces show AMPAR EPSCs before and after ZX1. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application, with control data from 1D. ‘HFS + APV’ (n=9) reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP (n=5). One-way ANOVA/Bonferroni, *p=0.003. Values represent mean ± SEM. Star (*) indicates p<0.05.

Journal: bioRxiv

Article Title: Bidirectional Long-Term Synaptic Zinc Plasticity at Mouse Glutamatergic Synapses

doi: 10.1101/320671

Figure Lengend Snippet: (A) Time course of AMPAR EPSC amplitude before and after HFS in the presence of APV (50 μM), and before and after subsequent ZX1 application. EPSC % baseline after HFS (mins. 19-23): n=9, *p=0.0008, one-sample t test vs. 100%. (B) Same time course as in A but in the presence of LY367385 (100 μM), MPEP (4 μM), and APV (50 μM). EPSC % baseline after HFS (mins. 19-23): n=6, *p=0.041, one-sample t test vs. 100%. For (A-B) , star (*) indicates significant LTP. To examine ZX1 potentiation after HFS, similar approach and renormalization as in 1C was performed. Red line shows the time course of AMPAR EPSC amplitude before and after ZX1 application in control replotted from 1B . Example traces show AMPAR EPSCs before and after ZX1. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application, with control data from 1D. ‘HFS + APV’ (n=9) reduced ZX1 potentiation compared to control; this reduction was blocked by LY367385 and MPEP (n=5). One-way ANOVA/Bonferroni, *p=0.003. Values represent mean ± SEM. Star (*) indicates p<0.05.

Article Snippet: The following drugs were purchased from HelloBio: SR95531 hydrobromide, DL-AP5, DNQX disodium salt, ifenprodil, MPEP hydrochloride, LY367385, and (S)-3,5-Dihydroxyphenylglycine (DHPG).

Techniques:

(A) Time course of AMPAR EPSC amplitude before and after LFS (5 Hz, 3 min), and before and after subsequent ZX1 application (cyan); and similar time course in interleaved control experiments (without LFS, red). (B) Same time course as in A but in the presence of LY367385 (100 μM) and MPEP (4 μM) (green). EPSC % baseline after LFS (mins. 20-24): n=6, *p=0.006, one-sample t test vs. 100%. Star (*) indicates significant LTD. Red line shows similar time course in controls replotted from A . For (A-B) , to examine the ZX1 potentiation after LFS, similar approach and renormalization as in 1C was performed. Example traces show AMPAR EPSCs before and after ZX1. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘LFS’: n=6; ‘LFS + LY367385, MPEP’: n=6. LFS increased ZX1 potentiation compared to control; this increase was blocked by LY367385 and MPEP. One-way ANOVA/Bonferroni, *p=0.02. The increase in ZX1 potentiation is termed Z-LTP. Values represent mean ± SEM. Star (*) indicates p<0.05.

Journal: bioRxiv

Article Title: Bidirectional Long-Term Synaptic Zinc Plasticity at Mouse Glutamatergic Synapses

doi: 10.1101/320671

Figure Lengend Snippet: (A) Time course of AMPAR EPSC amplitude before and after LFS (5 Hz, 3 min), and before and after subsequent ZX1 application (cyan); and similar time course in interleaved control experiments (without LFS, red). (B) Same time course as in A but in the presence of LY367385 (100 μM) and MPEP (4 μM) (green). EPSC % baseline after LFS (mins. 20-24): n=6, *p=0.006, one-sample t test vs. 100%. Star (*) indicates significant LTD. Red line shows similar time course in controls replotted from A . For (A-B) , to examine the ZX1 potentiation after LFS, similar approach and renormalization as in 1C was performed. Example traces show AMPAR EPSCs before and after ZX1. (C) Average ZX1 potentiation (% increase from baseline) during the last 5 min of ZX1 application. ‘Control’: n=5; ‘LFS’: n=6; ‘LFS + LY367385, MPEP’: n=6. LFS increased ZX1 potentiation compared to control; this increase was blocked by LY367385 and MPEP. One-way ANOVA/Bonferroni, *p=0.02. The increase in ZX1 potentiation is termed Z-LTP. Values represent mean ± SEM. Star (*) indicates p<0.05.

Article Snippet: The following drugs were purchased from HelloBio: SR95531 hydrobromide, DL-AP5, DNQX disodium salt, ifenprodil, MPEP hydrochloride, LY367385, and (S)-3,5-Dihydroxyphenylglycine (DHPG).

Techniques: